NCT06954740 (MSC-AKI-001) is a Phase 2 clinical trial of Amimestrocel in Acute Kidney Injury, sponsored by Chinese PLA General Hospital.

Who is sponsoring NCT06954740?

NCT06954740 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT06954740?

Interventions in NCT06954740: Amimestrocel.

What condition does NCT06954740 study?

NCT06954740 studies Acute Kidney Injury.

Is NCT06954740 still recruiting?

NCT06954740 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT06954740: MSC-AKI-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury

Recruiting now Phase 2 Last updated 8 September 2025

What this trial tests

Phase 2 trial testing Amimestrocel in Acute Kidney Injury in 50 participants. Currently enrolling.

Timeline

10 June 2025

Primary endpoint
15 May 2026

15 May 2028

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	10 June 2025
Primary completion	15 May 2026
Estimated completion	15 May 2028
Sites	6 locations across China

Drugs / interventions tested

Amimestrocel — full drug profile →

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 75, any sex, with Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is to evaluate the efficacy and safety of Amimestrocel (human umbilical cord mesenchymal stromal cells) in the treatment of AKI patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Innovative strategies to enhance MSCs efficacy in acute kidney injury (Review).
Zou Y, Dai J, Fu J, Wang H, et al · · 2025 · PMID 40910259 · DOI 10.3892/ijmm.2025.5620

Verify or expand the search:

Other trials of Amimestrocel

Trials testing the same drug.

NCT06969807 — Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease · Phase 2 · recruiting

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06954740 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06954740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing